Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Fundamental restructuring of the business portfolio, management reforms, and deeper penetration of existing markets. In the healthcare business, results benefited from a recovery in demand following price revisions and the addition of new cross-border e-commerce channels. In the plastic products business, contributions came from passing higher costs through to prices, eliminating and adjusting unprofitable products, and reviewing manufacturing costs. Persistently high energy prices, higher manufacturing costs due to the weaker yen, and the withdrawal from the nursing care business also affected results.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥5,911 million (YoY +3.9%) |
| Operating profit | ¥180 million |
| Ordinary income | ¥587 million (YoY +12.4%) |
| Profit attributable to owners of the parent | ¥283 million (YoY -27.8%) |
| Net income per share | ¥26.11 |
| Operating Margin | Current fiscal year 3.1 % / Previous period -0.6 % |
| Equity ratio | End of the current fiscal period 60.6 % / End of previous period 58.2 % |
| Total assets | ¥19,151 million |
| Net assets | ¥11,886 million |
| Cash flows from operating activities | ¥587 million |
| Cash flows from investing activities | ¥6 million |
| Cash flows from financing activities | ¥-807 million |
| Cash and cash equivalents at end of period | ¥1,737 million |
| Full-year earnings forecast | Net Sales ¥6,400 million (YoY +8.3%) / Operating profit ¥380 million (YoY +112.8%) / Ordinary income ¥250 million (YoY -57.3%) / Net income ¥60 million (YoY -78.7%) |
| Annual Dividend Forecast | ¥10 → ¥10（0.0%） |
| Payout ratio | 38.3% for the fiscal year ended March 2026; forecast 180.9% for the fiscal year ending March 2027 |
| Segment revenue | Healthcare Business ¥4,675 million (YoY +9.5%), Plastic Products Business ¥1,190 million (YoY -5.4%), Other Businesses ¥44 million (YoY -71.8%) |
| Segment profit | Healthcare Business ¥762 million (YoY +24.7%), Plastic Products Business ¥-35 million, Other Businesses ¥-43 million |
| Depreciation and amortization | ¥721 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥103,555 thousand / Extraordinary loss Loss on disposal and sale of non-current assets ¥39,791 thousand, Impairment loss on investment securities ¥19,990 thousand, Loss on debt waiver ¥30,479 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 1 company (有限会社サンクロード) |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 10,937,449 shares |
| Treasury Shares at Period-End | 81,450 shares |
| Factors Behind Changes in Business Performance | Fundamental restructuring of the business portfolio, management reforms, and deeper penetration of existing markets. In the healthcare business, results benefited from a recovery in demand following price revisions and the addition of new cross-border e-commerce channels. In the plastic products business, contributions came from passing higher costs through to prices, eliminating and adjusting unprofitable products, and reviewing manufacturing costs. Persistently high energy prices, higher manufacturing costs due to the weaker yen, and the withdrawal from the nursing care business also affected results. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company pursued a fundamental restructuring of its business portfolio, management reforms, and deeper penetration of existing markets. In the healthcare business, results benefited from a recovery in demand following price revisions and the addition of new cross-border e-commerce channels. In the plastic products business, contributions came from passing higher costs through to selling prices, eliminating and adjusting unprofitable products, and reviewing manufacturing costs. These benefits were offset by persistently high energy prices, higher manufacturing costs at the Malaysian operations due to the weaker yen, and the withdrawal from the nursing care business. Foreign exchange gains of ¥488 million were recorded in ordinary income.